TG Therapeutics Inc

+0.34 (+1.11%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)4.43B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.97 Million
Adjusted EPS-$0.56
See more estimates
10-Day MA$30.23
50-Day MA$29.47
200-Day MA$40.17
See more pivots

TG Therapeutics Inc Stock, NASDAQ:TGTX

2 Gansevoort Street, 9th floor, New York, New York 10014
United States of America
Phone: +1.212.554.4484
Number of Employees: 272


TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.